Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...

Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...

Amgen AMGN announced encouraging new data from its interim analysis of the global late-stage study evaluating Imdelltra ...

While the approval is a historic event for the BiTE drug class in solid tumours, the market share opportunity is restricted ...

Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease ...

THOUSAND OAKS, Calif., June 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle ...

Amgen said interim results from a Phase 3 trial showed Imdelltra reduced the risk of death and other benefits for patients with small cell lung cancer.

The Phase 3 DeLLphi-304 trial data presented at ASCO 2025 showed that Imdelltra® (tarlatamab-dlle) reduced the risk of death ...

1 The topline results from DeLLphi-304 demonstrate overwhelming clinical benefit for people living with this devastating disease and affirm IMDELLTRA as standard of care," said Jay Bradner ...

Amgen AMGN announced encouraging new data from its interim analysis of the global late-stage study evaluating Imdelltra (tarlatamab-dlle) for treating patients with small cell lung cancer (SCLC ...

Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended ...